AEYE is up +392.76% since Feb ’24 pick Unlock All Top Buy Picks
Chemed (CHE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Earnings Preview: Chemed (CHE) Q3 Earnings Expected to Decline

02:00pm, Monday, 24'th Oct 2022 Zacks Investment Research
Chemed (CHE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Natixis Vaughan Nelson Select Fund and its ETF counterpart are more diversified than the S&P 500 because of factor analysis.
CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the third quarter ended September 30, 2022, on Monday, October 31, 2022, followin

Is the Options Market Predicting a Spike in Chemed (CHE) Stock?

12:38pm, Friday, 07'th Oct 2022 Zacks Investment Research
Investors need to pay close attention to Chemed (CHE) stock based on the movements in the options market lately.
Investors need to pay close attention to Chemed (CHE) stock based on the movements in the options market lately.

Here's Why You Should Retain Chemed (CHE) Stock for Now

04:49pm, Thursday, 06'th Oct 2022 Zacks Investment Research
Investors are optimistic about Chemed's (CHE) Roto-Rooter business, which is witnessing continued demand for plumbing, drain cleaning services and water restoration services.
Investors are optimistic about Chemed's (CHE) Roto-Rooter business, which is witnessing continued demand for plumbing, drain cleaning services and water restoration services.

Option Care (OPCH) Stock Jumps 8.9%: Will It Continue to Soar?

02:24pm, Thursday, 29'th Sep 2022 Zacks Investment Research
Option Care (OPCH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the

Chemed (CHE) Roto-Rooter Business Grows, VITAS Admission Dips

03:41pm, Wednesday, 28'th Sep 2022 Zacks Investment Research
The performance of Chemed's (CHE) VITAS business is somewhat offset by a geographically weighted average Medicare reimbursement rate increase.
The performance of Chemed's (CHE) VITAS business is somewhat offset by a geographically weighted average Medicare reimbursement rate increase.

Chemed's (CHE) Roto-Rooter Growth Aids, Macro Challenges Ail

04:46pm, Friday, 02'nd Sep 2022 Zacks Investment Research
Chemed's (CHE) VITAS segment revenue decline during the second quarter gets somewhat offset by a geographically weighted average Medicare reimbursement rate increase of nearly 1.3%.
Chemed's (CHE) VITAS segment revenue decline during the second quarter gets somewhat offset by a geographically weighted average Medicare reimbursement rate increase of nearly 1.3%.

Here's Why You Should Hold on to Chemed (CHE) Stock Now

04:52pm, Thursday, 01'st Sep 2022 Zacks Investment Research
Investors are optimistic about Chemed's (CHE) better-than-expected earnings and impressive Roto-Rooter results.

PNTG vs. CHE: Which Stock Should Value Investors Buy Now?

03:40pm, Wednesday, 31'st Aug 2022 Zacks Investment Research
PNTG vs. CHE: Which Stock Is the Better Value Option?
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE